Establishing Liposome-Immobilized Dexamethasone-Releasing PDMS Membrane for the Cultivation of Retinal Pigment Epithelial Cells and Suppression of Neovascularization
暂无分享,去创建一个
Shih-Jen Chen | A. Yarmishyn | Yi-ping Yang | Chi-Hsien Peng | Yueh Chien | Yi-Ying Lin | Chih-Chien Hsu | De-Kuang Hwang | Mong-Lien Wang | Ke-Hung Chien | Tzu-Wei Lin
[1] P. D. de Jong,et al. Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.
[2] A. Bird,et al. Therapeutic targets in age-related macular disease. , 2010, The Journal of clinical investigation.
[3] P. Luthert,et al. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. , 2004, Investigative ophthalmology & visual science.
[4] C. Mailhos,et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. , 2006, The American journal of pathology.
[5] M. Nordlund,et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. , 2019, Journal of cataract and refractive surgery.
[6] Usha Chakravarthy,et al. Clinical classification of age-related macular degeneration. , 2013, Ophthalmology.
[7] G. Storm,et al. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo , 2015, The Prostate.
[8] S. Antimisiaris,et al. Dexamethasone Incorporating Liposomes: Effect of Lipid Composition on Drug Trapping Efficiency and Vesicle Stability , 2007, Drug delivery.
[9] S. Bakri,et al. Review of Combination Therapies for Neovascular Age-Related Macular Degeneration , 2011, Seminars in ophthalmology.
[10] N. Vakalis,et al. Intravitreal Combination of Dexamethasone Sodium Phosphate and Bevacizumab in The Treatment of Exudative AMD , 2015, Scientific Reports.
[11] R. Olabisi,et al. Scaffolds for retinal pigment epithelial cell transplantation in age-related macular degeneration , 2017, Journal of tissue engineering.
[12] S. Chiou,et al. Expression profiling of cell-intrinsic regulators in the process of differentiation of human iPSCs into retinal lineages , 2018, Stem Cell Research & Therapy.
[13] P. Rosenfeld,et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies , 2015, The Lancet.
[14] C. Regillo,et al. Preferred therapies for neovascular age-related macular degeneration , 2012, Current opinion in ophthalmology.
[15] Adnan Tufail,et al. Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration , 2018, Nature Biotechnology.
[16] Mark S. Humayun,et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration , 2018, Science Translational Medicine.
[17] Takashi Daimon,et al. Autologous Induced Stem‐Cell–Derived Retinal Cells for Macular Degeneration: Brief Report , 2017, The New England journal of medicine.
[18] Benjamin J. Thomas,et al. Simultaneous Dexamethasone Intravitreal Implant and Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration Resistant to Anti-VEGF Monotherapy , 2017, Journal of vitreoretinal diseases.
[19] A. Ahuja,et al. Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer. , 2013, Investigative ophthalmology & visual science.
[20] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[21] B. Kuppermann,et al. Corticosteroids and Anti-Complement Therapy in Retinal Diseases. , 2016, Handbook of experimental pharmacology.
[22] Jennifer I. Lim,et al. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.
[23] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[24] W. Amoaku,et al. Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in vitro. , 2016, Experimental eye research.
[25] A. Pinna,et al. Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study , 2018, Journal of ophthalmology.
[26] Y. Tai,et al. Microdevice-based cell therapy for age-related macular degeneration. , 2014, Developments in ophthalmology.
[27] J. Roider,et al. Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.
[28] P. Dubruel,et al. Generation of hESC-derived retinal pigment epithelium on biopolymer coated polyimide membranes. , 2012, Biomaterials.
[29] S. Chiou,et al. Corneal repair by human corneal keratocyte-reprogrammed iPSCs and amphiphatic carboxymethyl-hexanoyl chitosan hydrogel. , 2012, Biomaterials.
[30] S. Chiou,et al. Laminin modification subretinal bio-scaffold remodels retinal pigment epithelium-driven microenvironment in vitro and in vivo , 2016, Oncotarget.